GNMSF (Genmab AS) Total Inventories : $11 Mil (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is Genmab AS Total Inventories?

Genmab AS's total inventories for the quarter that ended in Sep. 2024 was $11 Mil. Genmab AS's average total inventories from the quarter that ended in Jun. 2024 to the quarter that ended in Sep. 2024 was $8 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Genmab AS's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was $33.63.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Genmab AS's Days Inventory for the three months ended in Sep. 2024 was 17.70.

Inventory Turnover measures how fast the company turns over its inventory within a year. Genmab AS's Inventory Turnover for the quarter that ended in Sep. 2024 was 5.16.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Genmab AS's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.01.

Genmab AS Total Inventories Historical Data

The historical data trend for Genmab AS's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Total Inventories Chart

Genmab AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

8.34

Genmab AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Inventories	Get a 7-Day Free Trial															10.02	8.34	15.45	5.19	10.57

Genmab AS Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Genmab AS (OTCPK:GNMSF) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Genmab AS's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is

	Net-Net Working Capital Per Share (Q: Sep. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2577.851	+	0.75 * 939.268	+	0.5 * 10.569	-	1151.831
-	0	-	0)	/	63.5136
=	33.63

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Genmab AS's Days Inventory for the three months ended in Sep. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2024 )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
	=	7.8805	/	40.637	*	365 / 4
	=	17.70

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Genmab AS's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2024 )	/	Average Total Inventories (Q: Sep. 2024 )
	=	40.637	/	7.8805
	=	5.16

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Genmab AS's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	7.8805	/	824.65
	=	0.01

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Genmab AS Total Inventories Related Terms

Thank you for viewing the detailed overview of Genmab AS's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (OTCPK:GNMSF) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

GMAB:USA GMABc:UK 0MGB:UK GMAB:Denmark GE91:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.